Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,089 across all filing types
Latest filing 2020-02-26 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
2019年度业绩快报
Earnings Release Classification · 95% confidence The document is titled '2019 年度业绩快报' which translates to '2019 Annual Performance Express Report' or '2019 Annual Earnings Quick Report'. It contains preliminary financial data for the year 2019, including revenue, profit, net income, and other financial metrics. The document explicitly states that the data is preliminary, unaudited, and subject to change in the final annual report. It also mentions that the detailed audited data will be disclosed in the 2019 Annual Report. The document is relatively short (1740 characters) and serves as an initial earnings announcement rather than a full annual report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the correct classification is Earnings Release (ER). FY 2019
2020-02-26 Chinese
关于特定股东股份减持计划时间届满并拟继续减持公司股份的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding a specific shareholder's plan to reduce their shareholding in the company, including details of past share reductions and a new planned reduction. It includes information about the shareholder, the number of shares to be reduced, the method of reduction, and compliance with relevant regulations. The document does not contain financial statements or detailed financial performance data. It is a regulatory announcement about shareholding changes by a major shareholder but does not meet the criteria for a Major Shareholding Notification (MRQ) since it focuses on a reduction plan and completion rather than crossing ownership thresholds. It is not a full financial report or earnings release. Therefore, the best fitting category is Transaction in Own Shares (POS), which covers company share repurchases or sales, or in this case, shareholder share reduction plans. However, since the shareholder is not the company itself but a specific shareholder reducing shares, and the document is about a shareholder's reduction plan, the closest category is Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. Given the document's focus on a shareholder's reduction plan and shareholding changes, MRQ is the most appropriate classification.
2020-02-24 Chinese
上海荣正投资咨询股份有限公司关于公司2019年限制性股票激励计划预留授予及回购注销部分限制性股票相关事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is an Independent Financial Advisor Report related to a 2019 restricted stock incentive plan for Xiamen Aide Biomedical Technology Co., Ltd. It discusses the approval, authorization, grant conditions, impact on financial status, and repurchase and cancellation of restricted stocks. The report includes detailed analysis and opinions from the financial advisor, references to regulatory compliance, and legal frameworks such as the Company Law and Securities Law. It is not a full annual or interim financial report, nor is it a simple announcement or certification. The document is a standalone advisory report focusing on the stock incentive plan and related financial and legal matters, fitting the definition of an Audit Report / Information (AR) as it includes applied accounting principles and regulatory compliance analysis but is not a full annual report or earnings release. Q1 2020
2020-02-14 Chinese
独立董事关于相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of a company regarding several corporate governance matters, including the granting of restricted stock under an incentive plan, use of idle raised funds for cash management, adjustment of stock incentive plan terms, and repurchase and cancellation of restricted stock. It references compliance with laws and regulations, board decisions, and shareholder interests. The content focuses on governance and management opinions rather than financial results or audit findings. It does not contain financial statements or earnings data, nor is it a simple announcement or certification. The document fits best under Board/Management Information (MANG) as it relates to board-level decisions and management governance matters, particularly about stock incentive plans and related corporate actions.
2020-02-14 Chinese
监事会关于公司2019年限制性股票激励计划预留授予部分激励对象名单的核查意见
Board/Management Information Classification · 95% confidence The document is a formal announcement from the supervisory board of a company regarding the verification of the list of incentive recipients under a 2019 restricted stock incentive plan. It discusses compliance with relevant laws and regulations, qualifications of the incentive recipients, and confirms the legality and validity of the incentive plan participants. There is no financial data, earnings information, or detailed report content. The document is an official announcement related to management and governance matters, specifically about stock incentive plans and compliance. This fits best under Board/Management Information (MANG) as it relates to management decisions and disclosures about incentive plans and personnel qualifications.
2020-02-14 Chinese
第二届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the Supervisory Board of Xiamen Aide Biomedical Technology Co., Ltd. It details resolutions passed during the 11th meeting of the 2nd Supervisory Board, including approval of stock incentive grants, use of idle raised funds for cash management, adjustments to the 2019 restricted stock incentive plan, and repurchase and cancellation of restricted stocks. The document includes voting results and compliance with relevant laws and regulations. It is not a full financial report, earnings release, or management discussion, but rather a formal announcement of board resolutions and decisions. The document length is short (2019 characters) and it is a meeting resolution announcement. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement of supervisory board decisions and approvals, not a full report or presentation.
2020-02-14 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.